Ziconotide (Prialt)
FDA-approved synthetic conotoxin peptide — a non-opioid analgesic for severe chronic pain, derived from cone snail venom.
At a glance
What it is: FDA-approved synthetic conotoxin peptide — a non-opioid analgesic for severe chronic pain, derived from cone snail venom..
Primary research applications:
- Severe, refractory chronic pain in patients intolerant of or refractory to other analgesics (FDA-approved indication)
- Intrathecal pain management research
Editorial summary: Ziconotide is the synthetic version of ω-conotoxin MVIIA, a peptide originally isolated from the venom of the cone snail Conus magus. It is an FDA-approved (2004) intrathecal analgesic for severe chronic pain — one of the few approved non-opioid alternatives for patients who have failed other options. The narrow therapeutic index and intrathecal-only delivery limit its use to specialized pain medicine settings.
- Class / structure
- Synthetic 25-amino-acid ω-conotoxin MVIIA (cone snail venom-derived)
- Half-life
- ~4.6 hours (intrathecal CSF)
- First described
- Approved 2004 (Elan / Eisai / Jazz Pharmaceuticals)
- Regulatory status
- FDA-approved 2004 for severe chronic pain via intrathecal infusion only
What is Ziconotide?
Ziconotide is a 25-amino-acid synthetic peptide identical to ω-conotoxin MVIIA, originally derived from cone snail venom. It blocks N-type voltage-gated calcium channels (Cav2.2) on primary afferent nerve terminals in the spinal cord, preventing release of pain-signaling neurotransmitters.[1]
Discovery and development
Ziconotide is the synthetic version of ω-conotoxin MVIIA, a peptide isolated in the 1980s from the venom of the cone snail Conus magus. The peptide's potency at neuronal N-type voltage-gated calcium channels — and the role of those channels in nociceptive signaling in the spinal cord — drove its development as a non-opioid analgesic for severe pain.
FDA approval in 2004 (under the brand name Prialt) made ziconotide one of the few non-opioid alternatives for severe chronic pain that had failed other treatments. Its delivery requirement — intrathecal infusion only — limits its use to specialized pain medicine settings with implanted intrathecal pump systems.
Mechanism of action
Selective antagonist of N-type voltage-gated calcium channels (Cav2.2) on presynaptic terminals of primary afferent neurons in the dorsal horn of the spinal cord. Channel blockade prevents calcium-mediated release of substance P, glutamate, and CGRP — the key pain-signaling neurotransmitters at the spinal level. Unlike opioids, ziconotide acts entirely on a non-opioid pathway and does not produce tolerance or dependence in the way opioids do.
Pharmacokinetics
Intrathecal delivery only (oral or IV would not reach the spinal cord targets and would produce systemic toxicity). CSF half-life approximately 4.6 hours. Continuous infusion through implanted intrathecal pump is the standard delivery method.
What the research shows
The peer-reviewed literature on Ziconotide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Provides analgesia in severe refractory chronic pain | Phase 3 evidence | Established |
| Avoids opioid tolerance and dependence | Mechanism distinct from opioids; supported by long-term clinical experience | Supported |
| Useful for non-severe pain | Not the indication; risk-benefit unfavorable for milder pain | Unsupported |
| Safe and well-tolerated as a general analgesic | Narrow therapeutic index; CNS adverse events common | Uncertain |
Reported user experiences
How the research describes administration
Intrathecal continuous infusion only via implanted pump. Slow dose titration is essential to manage CNS adverse events. Use is restricted to specialized pain medicine programs.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Ziconotide is one of the more interesting venom-derived peptide therapeutics in modern medicine — a snail-venom toxin synthesized as a non-opioid analgesic for the small population of patients who have failed other options for severe chronic pain. The intrathecal-only delivery, narrow therapeutic index, and serious CNS adverse-event profile keep its use in specialized hands, but for the appropriate patients it offers a fundamentally different mechanism of pain relief from any other approved analgesic class.
Frequently asked questions
Why is ziconotide given intrathecally rather than orally or by injection?
The N-type calcium channel targets are in the spinal cord, and systemic delivery would produce severe cardiovascular and CNS toxicity at therapeutic doses. Intrathecal delivery places the drug at its target while limiting systemic exposure.
Is ziconotide a peptide therapeutic in the way GLP-1 agonists are?
Yes — it is a 25-amino-acid synthetic peptide, identical to a naturally-occurring conotoxin. The peptide-therapeutic framing applies, even though the indication and delivery method are very different from the metabolic peptides that dominate the broader peptide-therapeutic conversation.
Does ziconotide cause tolerance like opioids?
One of its principal advantages is that long-term intrathecal use does not appear to produce the pharmacologic tolerance that affects opioid therapy. The mechanism is entirely non-opioid, and the absence of opioid-type tolerance is part of the rationale for its use in patients who have exhausted opioid options.
References
- Olivera BM, et al. Conotoxins. J Biol Chem. 1991;266(33):22067-22070. https://pubmed.ncbi.nlm.nih.gov/1939228/
- Staats PS, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63-70. https://pubmed.ncbi.nlm.nih.gov/14709577/
- Rauck RL, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31(5):393-406. https://pubmed.ncbi.nlm.nih.gov/16716870/